The settlement, reached June 26, prohibits the company from promoting opioids through any means and bans lobbying about opioid products at the federal, state and local levels.
The last time Johnson & Johnson marketed opioids in the U.S. was 2015, and the drugmaker said it discontinued its opioid business in 2020.
To resolve claims that it fueled the opioid epidemic, Johnson & Johnson will pay New York $230 million over nine years. It will also pay an additional $30 million in the first year New York’s executive chamber signs into law new legislation to create an opioid settlement fund.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
